Dominic Duke

FSA, CERA, MAAA

Senior Consulting Actuary

Windsor, CT, US

Main +1 860 687 0100 | Office +1 860 687 0124

Dominic Duke is a senior consulting actuary with the Hartford office of Milliman. He joined the firm in 2023.

Loading component...

Experience

Dominic is a credentialed actuary with 15 years of experience across the PBM, Part D plan sponsor, and pharmaceutical manufacturer spaces. He spent nine years at CVS Health, ending his time there as the signing Part D bid actuary for SilverScript Insurance Company, the largest Part D plan sponsor in the U.S. at the time. In that role he was responsible for coordinating and submitting compliant and competitive bids, working closely with formulary, trade, network, regulatory, adjudication, and other departments across the organization.

Dominic then spent four years as chief actuary of Novartis Pharmaceuticals Corporation, primarily responsible for Part D market access negotiations with the largest PBMs across a number of therapeutical classes and modeling associated impacts of the Inflation Reduction Act.

Dominic is currently responsible for building out Milliman’s Medicare Intelligence product and all underlying CMS ‘Research Identifiable File’ initiatives for the Milliman CMH Health Practice. With five years’ experience working with CMS and its ‘VRDC’ environment, his focus is on leveraging one the most valuable data assets in U.S. healthcare to provide unprecedented levels of strategic insights for Milliman’s Medicare-focused customers.

Professional Designations

Fellow, Society of Actuaries
Chartered Enterprise Risk Analyst
Member, American Academy of Actuaries

Education

MBA, Business Administration and Management, Bryant University, RI
BSc, International Economics, University of Nottingham, UK

Loading component...

Publications

Read their latest work

Article

Early 2025 Medicare Part D claims show continued increase in non-low income specialty drug spend

15 April 2025 - by Dominic Duke, Madeleine Feller, David M. Liner

Medicare Part D claims show non-low income drug spending rose 43% in early 2025 versus a year earlier, while costs for other categories also accelerated.

Article

MedIntel Insights: Early look at Medicare Prescription Payment Plan enrollment

15 April 2025 - by Dominic Duke, Madeleine Feller, David M. Liner

MedIntel Insights: We give an early glimpse of Medicare Prescription Payment Plan enrollment, which had 179,000 beneficiaries participate in its first two months.

Dominic Duke

Loading component...

Experience

Loading component...

Read their latest work

Early 2025 Medicare Part D claims show continued increase in non-low income specialty drug spend

MedIntel Insights: Early look at Medicare Prescription Payment Plan enrollment

CHOOSE A LOCATION AND LANGUAGE

Dominic Duke

Experience

CHOOSE A LOCATION AND LANGUAGE